Moderna, Inc. (MUN:0QF)
Germany · Delayed Price · Currency is EUR | Market Cap | 51.28B +507.5% |
| Revenue (ttm) | 1.95B -27.6% |
| Net Income | -2.76B |
| EPS | -7.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,538 |
| Open | 136.78 |
| Previous Close | 136.16 |
| Day's Range | 125.48 - 136.78 |
| 52-Week Range | 20.18 - 143.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Was Moderna Stock's 440% Surge Hiding In Plain Sight?
This article was written by Doug Nathman, with research by his team at Trefis.
Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide use
The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited.
Moderna Stock (MRNA) Rises 12.5% Today Following Phase 3 mRNA Cancer Vaccine Win with Merck
Biotech firm Moderna ($MRNA) saw its stock rise 12.5% today, building on a multi-day rally after releasing positive Phase 3 trial data for its personalized mRNA cancer vaccine. Developed alongside…
What Happens if Moderna's Cancer Vaccine Works
Moderna and Merck's personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.
Moderna upgraded to Peer Perform from Underperform at Wolfe Research
Wolfe Research upgraded Moderna (MRNA) to Peer Perform from Underperform without a price target The firm says the positive melanoma trial de-risks the intismeran platform. Wolfe now sees a “much…
Moderna CEO warns China is investing heavily in mRNA as Beijing challenges US in biotechnology
Moderna's 177% stock surge followed its mRNA cancer vaccine success, but CEO Stéphane Bancel says China's biotechnology investments pose a threat.
Emily Field: Large pharma companies are going to continue looking at biotech
Emily Field, Head of U.S. Biopharma Equity Research at Barclays, says biotech is gaining momentum as M&A returns, capital markets reopen and breakthroughs in cancer vaccines fuel investor interest.
Moderna Is Betting Big on Its Cancer Vaccine. This Is What Wall Street Wants to See.
Moderna's management sees significant long-term potential in intismeran autogene, Barclays says.
Moderna price target raised to $125 from $48 at Barclays
Barclays analyst Eliana Merle raised the firm’s price target on Moderna (MRNA) to $125 from $48 and keeps an Equal Weight rating on the shares. The stock at current levels…
Heard on the Street: Moderna's mRNA cancer vaccine marks a major leap in personalized oncology. But the financial math is sobering.
Personalized mRNA shots may prove neither as wide-reaching nor as lucrative as hoped.
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink
After years of layoffs, cash burn and political attacks on its core technology, Moderna's melanoma vaccine data notched the biotech company a much-needed win.
Moderna Soars 129% for the Week | Closing Bell
Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Sally Bakewell, Carol Massar and Emily Graffeo. -------- More...
Moderna Stock (MRNA) Jumps 13% Despite JPMorgan’s Sell Rating
Shares in Moderna ($MRNA) climbed by 13% to $151 per share on Friday afternoon. This came even after JPMorgan’s five-star analyst Jessica Fye repeated her Sell rating on the U.S.
Moderna, Robinhood, Ross Stores, and More Stocks That Explain Today's Market
Moderna shares rise to close out a week of wild swings, while crypto stocks extend their recent rally.
Moderna's personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped
Doctors and patients are excited about the possible breakthrough, but some analysts believe there's too much hype.
Moderna Is Up 350% Since Our Recommendation. Here's What to Do Next.
Moderna's breakthrough highlights a broader transformation, as AI accelerates the clinical development of therapies at a pace that would have seemed unimaginable a few years ago.
Moderna Stock Plunges 25%—Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough
$51.5 billion. That's Moderna's market valuation as of Thursday, marking a more than $18 billion decline from Wednesday's closing valuation of $69.6 billion.
How Moderna's Historic Short Squeeze Upended the AI Chip Trade
Moderna stock surged following positive cancer-vaccine data, burning short sellers and spilling over into the semi sector.
Moderna is paring back gains, but Merck stock remains a buy
Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial res...
Why Moderna Stock Is Plunging Today — and What Wall Street Sees Ahead
Moderna (NASDAQ:MRNA) stock is giving back part of Wednesday’s huge gain, falling about 18% on Thursday as Wall Street’s response to the latest cancer-vaccine results gives investors reason to cash…
Thursday's First Moves: Analysts Mixed on MRNA & MRK Rally, AAP & DE Earnings
Diane King Hall discusses the sharp sell-off in Advance Auto Parts (AAP) as the guidance shows strong headwinds. Deere (DE) offered plenty of strength in its earnings as construction revenues rise.